US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACRES Commercial Realty Corp.

19.29

+0.12500.65%

Volume:3.89K

Turnover:74.83K

Market Cap:143.79M

PE:16.77

High:19.45

Open:18.97

Low:18.97

Close:19.16

Loading ...

Overview Company News Filings

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Press Release: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Press Release: Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Promising Outlook for Acrivon Therapeutics: Buy Rating Affirmed on Strong ACR-368 Data and Strategic Growth Plans

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Sobi to present new data across its immunology portfolio at the ACR Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

ACRES Commercial Realty (ACR) Gets a Buy from JMP Securities

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACR/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACR\",,,,,undefined,":{"symbol":"ACR","market":"US","secType":"STK","nameCN":"ACRES Commercial Realty Corp.","latestPrice":19.285,"timestamp":1746030032288,"preClose":19.16,"halted":0,"volume":3892,"delay":0,"floatShares":7105800,"shares":7456150,"eps":1.149999,"marketStatus":"Trading","change":0.125,"latestTime":"04-30 12:24:04 EDT","open":18.9706,"high":19.4497,"low":18.9706,"amount":74827.02765999999,"amplitude":0.025005,"askPrice":19.67,"askSize":100,"bidPrice":18.88,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.149999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":19.16,"dividendRate":0.042779,"preHourTrading":{"tag":"盘前","latestPrice":19.99,"preClose":19.16,"latestTime":"08:38 EDT","volume":4,"amount":76.39,"timestamp":1746016702588},"postHourTrading":{"tag":"盘后","latestPrice":20.2,"preClose":19.16,"latestTime":"19:59 EDT","volume":741,"amount":14841.06,"timestamp":1745971163699},"volumeRatio":0.249649,"impliedVol":0.2004,"impliedVolPercentile":0.308},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACR\",,,,,undefined,":{"symbol":"ACR","floatShares":7105800,"roa":"1.41%","roe":"6.41%","lyrEps":1.191983,"volumeRatio":0.249649,"shares":7456150,"dividePrice":0.825,"high":19.4497,"amplitude":0.025005,"preClose":19.16,"low":18.9706,"week52Low":12.33,"pbRate":"0.33","psRate":"1.83","week52High":23.81,"institutionHeld":0.1601,"latestPrice":19.285,"eps":1.149999,"divideRate":0.042779,"volume":3892,"delay":0,"ttmEps":1.149999,"open":18.9706,"prevYearClose":16.15,"prevWeekClose":18.58,"prevMonthClose":21.67,"prevQuarterClose":21.67,"fiveDayClose":17.5,"twentyDayClose":21.28,"sixtyDayClose":17.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACR\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2483337338","title":"Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337338?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:02","pubTimestamp":1731618120,"startTime":"0","endTime":"0","summary":"– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –。Kronos Bio has been exploring the utility of KB-7898, a p300 KAT inhibitor, for autoimmune indications given the role of interferon regulatory factor 4  and p300 in B cells, T cells and other immune cells. The data demonstrates the ability of p300 KAT inhibition to modulate the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases.In the presentation titled, \"p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines\", the presenter, Dr. Peter Rahl, Vice President, Discovery Biology at Kronos, will summarize the experiments that led to the following key findings:. In ex vivo primary cell models, the authors demonstrated that p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ijRT4XFYumx4aXQz_S.WiQ--~B/aD0xOTM7dz0zNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/306fc5d57d77b3786b01ca1e604f81cb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ijRT4XFYumx4aXQz_S.WiQ--~B/aD0xOTM7dz0zNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/306fc5d57d77b3786b01ca1e604f81cb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kronos-bio-highlights-preclinical-data-210200776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4090","BK4110","BK4162","ACR","BK4139","CIA","BK4505","KRON","KRO"],"gpt_icon":0},{"id":"2483332212","title":"AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483332212","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483332212?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:00","pubTimestamp":1731618000,"startTime":"0","endTime":"0","summary":"MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA asthe First Potential Treatment tor IgG4-RD. Phase 4 AGILE Data Support Shortening KRYSTEXXA Infusion Time. THOUSAND OAKS, Calif., Nov. 14, 2024 /PRNewswire/ -- Amgen  today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology  Convergence 2024 conference in Washington, D.C., Nov. 14-19, 2024. New data showcase reduction in disease activityby UPLIZNA  in Immunoglobulin G4-Related Disease  and support shorter infusion times for KRYSTEXXA co-administered with weekly oral methotrexate 15 mg.\"These data add to the growing body of evidence for UPLIZNA and KRYSTEXXA and strengthen our commitment to developing new treatment options for rare diseases like IgG4-RD and uncontrolled gout,\" said Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen. \"Patients living with these debilitating conditions dese","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-presents-data-across-rare-210000210.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-presents-data-across-rare-210000210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1061106388.HKD","LU1057294990.SGD","SG9999001440.SGD","LU1571399168.USD","BK4581","RARE","ACR","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4139","LU0122379950.USD","LU0109394709.USD","LU2112291526.USD","LU0289739699.SGD","LU0868494617.USD","LU1023059063.AUD","IE0009355771.USD","LU2242652126.USD","BK4585","BK4566","IE00BJJMRZ35.SGD","LU0889565916.HKD","AMGN","LU1983299246.USD","BK4534","LU2242646821.SGD","IE00B2B36J28.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","BK4533","IE00B4R5TH58.HKD","BK4110","BK4588","PML","IE0002141913.USD"],"gpt_icon":0},{"id":"2483670807","title":"Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483670807","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483670807?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:01","pubTimestamp":1731596460,"startTime":"0","endTime":"0","summary":"Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis  Treated With KYV-101 Target Dose. KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed. Also at ACR Convergence 2024, Kyverna will present data on next-generation approaches, most notably with a poster on Ingenui-T, the Company's preclinical 3-day manufacturing process using autologous whole blood as starting material. Ingenui-T is designed to improve the patient experience by eliminating apheresis, leading to a potential for improved convenience, access and overall cost reduction. As the poster highlights, drug product from the Ingenui-T process manufactured with whol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/W4PdMGzxR8LSOetGHBXf6Q--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/51c107a1cce9fe9862ec80c3d9111c66","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/W4PdMGzxR8LSOetGHBXf6Q--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/51c107a1cce9fe9862ec80c3d9111c66"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kyverna-therapeutics-announces-patient-data-150100844.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kyverna-therapeutics-announces-patient-data-150100844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KYTX","BK4077","BK4022","ACR","BK4139","BK4230","CAR","BK4110","SLE"],"gpt_icon":0},{"id":"2483080209","title":"Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483080209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483080209?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:01","pubTimestamp":1731596460,"startTime":"0","endTime":"0","summary":"Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases  Cullinan will share details of global Phase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981359/0/en/Cullinan-Therapeutics-Announces-Preclinical-Data-for-CLN-978-a-CD19-directed-T-Cell-Engager-to-be-Presented-at-ACR-Convergence-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","CGEM","BK4110","RA","SLE","ACR"],"gpt_icon":0},{"id":"2483684386","title":"Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study","url":"https://stock-news.laohu8.com/highlight/detail?id=2483684386","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483684386?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:00","pubTimestamp":1731596400,"startTime":"0","endTime":"0","summary":"Adults with moderately-to-severely active Sjgren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels. Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjgren's diseasebased on results from the Phase 2 DAHLIAS study. Results also showed a significant reduction in IgG including autoantibody levels among patients receiving 15 mg/kg every two weeks, providing further evidence of nipocalimab's mechanism of action through interaction with the FcRn. Moreover, improvements in ClinESSDAI were generally greatest in the participants with the highest baseline levels of anti-Ro and anti-La autoantibodies, associated with substantial nipocalimab-induced reductions in IgG and total IgG autoantibodies.Many people living with SjD experience symptoms that interfere with daily activities and ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nipocalimab-demonstrates-significant-clinical-improvement-150000067.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nipocalimab-demonstrates-significant-clinical-improvement-150000067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FL","IE00BMG7P702.HKD","LU0128525689.USD","DAL","LU1244550494.USD","BK4581","IE00BMG7P587.USD","LU0310800965.SGD","LU1032955483.USD","BK4500","LU1221951046.USD","IE00BGHQF631.EUR","LU1894683348.USD","IE00BVYPNV92.GBP","LU1430594728.SGD","LU1732800096.USD","LU1066051225.USD","IE00B2B36J28.USD","LU2602419157.SGD","SG9999002232.USD","BK4568","JNJ","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","LU1674673428.USD","BK4007","IE00BZ18W456.USD","IE00BVYPNW00.USD","LU0795875086.SGD","CNS","D","IE0002270589.USD","IE00BJT1NW94.SGD","ACR","LU0320765646.SGD","LU1585245621.USD","LU0203347892.USD","BK4588","IE00BD4GTT62.SGD","LU0203345920.USD","IE00BMG7P694.USD","IE00B19Z3581.USD","LU0122379950.USD","LU1267930227.SGD","LU1732799900.SGD","LU0912757837.SGD","BK4585","IE00BMG7P819.SGD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2483713876","title":"Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483713876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483713876?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"– Clinical data from the RESET-Myositis and RESET-SLE trials, along with initial clinical data from the RESET-SSc trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 –。– 16 patients enrolled with 10 patientsdosed as of November 12 across the RESET clinical development program; 40 U.S. clinical sites actively recruiting patients –。– Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 –。– Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International –。PHILADELPHIA, Nov. 14, 2024  -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2024, and pro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cabaletta-bio-reports-third-quarter-120000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CABA","ACR","BK4139","BK4077","BK4110","CTA","CHRO","SLE"],"gpt_icon":0},{"id":"2483755418","title":"Press Release: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483755418","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483755418?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:50","pubTimestamp":1731585000,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:30 a.m. EST. CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update.\"We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now complete,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"Preliminary results from this study, being presented today and this week in a late-breaking poster at ACR Convergence 2024, are encouraging and demonstrate the potential of PRX-115 to be a promising uric-acid lowering treatment option for individuals ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","BK4110","BK4215","SG9999001176.SGD","BK4232","LU0058720904.USD","LU0225771236.USD","LU1023059063.AUD","BK4533","PFE","BK4139","TM","SG9999002224.SGD","IE00B19Z3B42.SGD","ACR","LU0122379950.USD","LU0321505868.SGD","BK4588","LU0306807586.USD","PK","LU0321505439.SGD","R","03160","LU0234572021.USD","SG9999001176.USD","BK4585","BK4568","BK4592","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","SG9999013999.USD","LU0868494617.USD","LU1883839398.USD","MAA","LU1894683264.USD","BK4534","IE000M9KFDE8.USD","BK4181","BK4581","SG9999011175.SGD","LU0170899867.USD","BK4218","BK4555","LU0289739699.SGD","PLX","BK4022","LU0306806265.USD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2483868143","title":"Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868143","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868143?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"CHATHAM, N.J., Nov.  13, 2024  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980651/28908/en/Tonix-Pharmaceuticals-Announces-Poster-Presentation-at-the-American-College-of-Rheumatology-ACR-Convergence-2024-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","AFG","BK4117","TNXP","BK4583","BK4107","BK4135","ACR","BK4139","CNS"],"gpt_icon":1},{"id":"2483141868","title":"Press Release: Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2483141868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483141868?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"-- Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition --. -- Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus  and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases --. SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024  -- Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent achievements and upcoming milestones.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4585","LU1363072403.SGD","CNS","LU2357305700.SGD","BK4110","BK4077","LU0971096721.USD","ACR","LU0006306889.USD","BK4516","LU0267386448.USD","LU1720051108.HKD","BK4504","LU0314104364.USD","LU0106261372.USD","BK4135","SLE","BK4007","IE00BKVL7J92.USD","LU1162221912.USD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1548497426.USD","LU0106831901.USD","BK4588","LU1074936037.SGD","BK4581","LU0320765646.SGD","LU1989772840.SGD","LU1989772923.USD","BK4534","LU0225283273.USD","ALMS","LU1668664300.SGD","LU0098860793.USD"],"gpt_icon":0},{"id":"2483833170","title":"Promising Outlook for Acrivon Therapeutics: Buy Rating Affirmed on Strong ACR-368 Data and Strategic Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2483833170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483833170?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:45","pubTimestamp":1731512714,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), retaining the price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-acrivon-therapeutics-buy-rating-affirmed-on-strong-acr-368-data-and-strategic-growth-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-acrivon-therapeutics-buy-rating-affirmed-on-strong-acr-368-data-and-strategic-growth-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACR","LENZ"],"gpt_icon":0},{"id":"2483000896","title":"MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2483000896","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483000896?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on bio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980229/0/en/MoonLake-Immunotherapeutics-starts-Phase-3-IZAR-program-of-the-Nanobody-sonelokimab-in-patients-with-active-psoriatic-arthritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ACR","MLTX","BK4139","MDA"],"gpt_icon":0},{"id":"2481040154","title":"Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481040154","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481040154?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:02","pubTimestamp":1731013320,"startTime":"0","endTime":"0","summary":"Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and Patient ScreeningLymphodepletion Selection Planne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/07/2977102/0/en/Allogene-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","CRS","SD","BK4110","ACR","IE00B7SZL793.SGD","LENZ","BK4006","BK4139","CAR","BK4022","BK4230","BK4213","IE00B19Z4B17.USD","SITC","IE0031619046.USD","RCC","BK4231","BK4080"],"gpt_icon":0},{"id":"2481128904","title":"Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481128904","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481128904?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"New data for investigational nipocalimab in Sjgren's Disease  and new research on the impact of TREMFYA  in psoriatic arthritis  will be highlighted across three oral sessions and a plenary session. Results from the Phase 2 DAHLIAS study of nipocalimab in SjD show nipocalimab met the primary endpoint with a reduction in ClinESSDAI score from baseline and other key efficacy endpoints at Week 24 compared with placebo, presented in a plenary session. Results from the PsABIOnd observational study highlight the patient-reported impact in psoriatic arthritis  disease burden following treatment with TREMFYA, presented as an oral presentation. SPRING HOUSE, Pa., Nov. 7, 2024 /PRNewswire/ -- Johnson & Johnson  announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology  2024 Annual Meeting. Presentations include three oral sessions and a plenary session, highlighting new data for investigational nipo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnson-advances-leadership-rheumatic-130000353.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-advances-leadership-rheumatic-130000353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0114720955.EUR","LU0882574055.USD","BK4568","BK4532","IE00BMG7P702.HKD","ACR","IE00BMG7P587.USD","RA","IE00B3T34201.USD","BK4592","IE00BD4GTV84.USD","LU0122379950.USD","LU0098860793.USD","IE00BMG7P694.USD","IE00B42XCP33.USD","IIM","LU0795875086.SGD","LU1066053197.SGD","LU1196500208.SGD","IE00BVYPNW00.USD","D","ET","IE0009355771.USD","LU1074936037.SGD","IE00BFTCPJ56.SGD","IE00BDGV0183.EUR","LU1032466523.USD","BK4590","BK4007","FL","BK4218","SLE","IE0002270589.USD","IE00BD4GTW91.USD","IE00BZ18W340.USD","LU1057294990.SGD","JNJ","LU1066051811.HKD","IE00B1BXHZ80.USD","LU0345769128.USD","BK4144","BK4566","IE00BD4GTT62.SGD","PK","BK4094","RF","LU0203347892.USD","PD","IE000M9KFDE8.USD","BK4550"],"gpt_icon":0},{"id":"2481990804","title":"Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481990804","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481990804?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:01","pubTimestamp":1730980860,"startTime":"0","endTime":"0","summary":"Global Phase 1 study of CLN-978 in systemic lupus erythematosus  cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025. CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025. \"We are making meaningful progress in executing our strategic plans for CLN-978 in autoimmune diseases while simultaneously advancing our oncology pipeline,\" said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics. \"We have secured clearance from the U.S. Food and Drug Administration  for our IND application and Human Research Ethics Committee  approval in Australia to initiate our global Phase 1 study for CLN-978 in moderate to severe SLE. These important regulatory clearances position us to share initial clinical data for CLN-978 in the fourth quarter of 2025. We also continue to make significant progress in advancing our oncology portfolio, with data from two of our key programs expected in 2025. For CLN-619, we remain on trac","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM","ACR","BK4110","SITC","BK4077","SLE","RA","BK4080","BK4231"],"gpt_icon":0},{"id":"2481702908","title":"Sobi to present new data across its immunology portfolio at the ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481702908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481702908?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:59","pubTimestamp":1730980740,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov. 07, 2024  -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB  , today announced the presentation of four abstracts that highlights data from its immunology portfolio at the ACR Convergence 2024 taking place in Washington, D.C. from November 14–19, 2024.Sobi’s commitment to delivering innovative treatments for people living with immunological diseases is seen in global studies spanning multiple disorders:. Results from two Phase 3 trials evaluating the effect on patient-reported outcomes in patients with chronic refractory gout treated with SEL-212.Initial data on the effect of anti-drug antibodies on serum uric acid  reduction and safety in response to treatment with SEL-212.DISSOLVE 1 Phase 3 study: Results of a post hoc analysis of sustained sUA reduction and safety of SEL-212 in patients with chronic refractory gout living in the United States.Results from a Phase 3 Study and a pooled analysis of two prospective trials evaluating ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x7YFyGf5t1TpmaBcFH5NNQ--~B/aD0yNzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c87171b9fa161c1111e7d2f803fd59a9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x7YFyGf5t1TpmaBcFH5NNQ--~B/aD0yNzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c87171b9fa161c1111e7d2f803fd59a9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sobi-present-data-across-immunology-115900677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2413666004.HKD","HSCT","ACR","BK4110","LU1620156130.USD","BK4086","SG9999001440.SGD","BK4077","BK4121","BK4530","PPD","MAS","LU0170899867.USD","LU1596574779.USD","BK4139","LU1721427968.SGD","LU1165135440.EUR","LU1543694498.USD","BK4588","LU1620156213.USD","LU2413665964.HKD","SLE","SWOBY","BIOVF","BK4561","BK4585"],"gpt_icon":0},{"id":"2481954624","title":"Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481954624","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481954624?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:00","pubTimestamp":1730926800,"startTime":"0","endTime":"0","summary":"ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis  anticipated in 1H25. Strong balance sheet with $202.1 million in cash, cash equivalents and short-term investments as of September 30, 2024. REDWOOD CITY, Calif. & BOSTON, November 06, 2024----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024.FDA clearance of IND amendment to evaluate ADI-001 in IIM and SPS. In October 2024, Adicet announced that the U.S. Food and Drug Administration  cleared the Company’s Investigational New Drug  amendment application to evaluate ADI-001 in IIM and SPS as part of the Phase 1 clinical trial in autoimmune diseases.Presented ADI-001 clinical biomarker data demonstrating robust tissue trafficking an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-reports-third-quarter-2024-210000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CAR","IIM","ACET","BK4110","BK4022","BK4230","SLE","ACR","BK4077"],"gpt_icon":0},{"id":"2481085775","title":"Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481085775","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481085775?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:00","pubTimestamp":1730808000,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, November 05, 2024----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology  Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune IndicationsSession Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases IIAbstract Number: 1866169Presenting Author: Monica Moreno, Ph.D.Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/E2BwQHr0trUKZ6AJmJh2mA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5eba4b981214073db274dba960d3dede","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/E2BwQHr0trUKZ6AJmJh2mA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5eba4b981214073db274dba960d3dede"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-present-american-college-120000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","BK4139","BK4107","AFG","ACET","ACR","BK4110"],"gpt_icon":0},{"id":"2480301122","title":"Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2480301122","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480301122?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:00","pubTimestamp":1730721600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov. 04, 2024  -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at American College of Rheumatology  Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024.“These preclinical data show that CLN-978 is a highly potent T cell engager that leads to deep B cell depletion, supporting the broad development of CLN-978 as a potential new therapeutic option for patients with autoimmune diseases,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “We look forward to continued collaboration with investigators and the patient community as we initiate our global Phase 1 clinical trial of CLN-978 in systemic lupus erythematosus and deliver on our mission to bring new standards of care to patients.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8YHWqKJllJrX4H7ePTYJSg--~B/aD02Mjk7dz0xMjAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/da6db52b96baf72a99e6f5ae010de81c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8YHWqKJllJrX4H7ePTYJSg--~B/aD02Mjk7dz0xMjAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/da6db52b96baf72a99e6f5ae010de81c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-present-preclinical-data-120000509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACR","BK4139","SLE","CGEM","BK4110","BK4077"],"gpt_icon":0},{"id":"2480505792","title":"ACRES Commercial Realty (ACR) Gets a Buy from JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2480505792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480505792?lang=en_us&edition=fundamental","pubTime":"2024-11-01 02:25","pubTimestamp":1730399121,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Chris Muller reiterated a Buy rating on ACRES Commercial Realty (ACR – Research Report) today and set a price target of $18....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acres-commercial-realty-acr-gets-a-buy-from-jmp-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acres-commercial-realty-acr-gets-a-buy-from-jmp-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4110","JMP","ACR"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":79,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACR\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":null,"defaultRemindTime":1746043200000,"name":null,"time":"Post Market","dateTimestamp":1745985600000,"actualEps":null},{"market":"US","date":"2025-03-05","symbol":"ACR","fiscalQuarterEnding":"2024/12","expectedEps":0.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741150800000,"reportTimeType":"post","actualEps":0.37},{"market":"US","date":"2024-10-30","symbol":"ACR","fiscalQuarterEnding":"2024/09","expectedEps":0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730260800000,"reportTimeType":"post","actualEps":0.14},{"date":"2024-07-31","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":0.28,"defaultRemindTime":1722456000000,"name":null,"time":"Post Market","dateTimestamp":1722398400000,"actualEps":null},{"date":"2024-05-01","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":0.35,"defaultRemindTime":1714593600000,"name":null,"time":"Post Market","dateTimestamp":1714536000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACR\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-28","value":0.16,"currency":"USD"},{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-28","value":0.64,"currency":"USD"},{"executeDate":"2015-12-29","recordDate":"2015-12-31","paymentDate":"2016-01-28","value":0.42,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-28","value":0.42,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-28","value":0.42,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1728360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACR","date":"2025-04-29","current":4.352296,"percent":0.554923,"low":-0.830359,"twenty":-0.283753,"median":3.931357,"eighty":5.92678,"high":14.204017,"avg":3.840809,"sd":3.112157,"marketCap":127378638},"quantilePoints":[{"date":"2020-05-01","current":2.391384,"twenty":2.417668,"median":4.354063,"eighty":23.644331,"marketCap":86008529},{"date":"2020-05-08","current":-0.476126,"twenty":2.408405,"median":4.354063,"eighty":23.64292,"marketCap":80316788},{"date":"2020-05-15","current":-0.385121,"twenty":2.399108,"median":4.34603,"eighty":23.635049,"marketCap":64965358},{"date":"2020-05-22","current":-0.385121,"twenty":2.391757,"median":4.34603,"eighty":23.624215,"marketCap":64965358},{"date":"2020-05-29","current":-0.375728,"twenty":2.375238,"median":4.342013,"eighty":23.616544,"marketCap":63380838},{"date":"2020-06-05","current":-0.537291,"twenty":2.268298,"median":4.337996,"eighty":23.60285,"marketCap":90634598},{"date":"2020-06-12","current":-0.572985,"twenty":2.233131,"median":4.327955,"eighty":23.60285,"marketCap":96655777},{"date":"2020-06-19","current":-0.49784,"twenty":2.128917,"median":4.313896,"eighty":23.595809,"marketCap":83979610},{"date":"2020-06-26","current":-0.482811,"twenty":1.847407,"median":4.307872,"eighty":23.582109,"marketCap":81444376},{"date":"2020-07-02","current":-0.452752,"twenty":1.820352,"median":4.29783,"eighty":23.582109,"marketCap":76373909},{"date":"2020-07-10","current":-0.447117,"twenty":1.812445,"median":4.281763,"eighty":23.567545,"marketCap":75423197},{"date":"2020-07-17","current":-0.454631,"twenty":1.79588,"median":4.247621,"eighty":23.561875,"marketCap":76690813},{"date":"2020-07-24","current":-0.450874,"twenty":1.778891,"median":4.229546,"eighty":23.561368,"marketCap":76057005},{"date":"2020-07-31","current":-0.418937,"twenty":1.77303,"median":4.197413,"eighty":23.561368,"marketCap":70669634},{"date":"2020-08-07","current":-0.389478,"twenty":1.767642,"median":4.169297,"eighty":23.561368,"marketCap":82171619},{"date":"2020-08-14","current":-0.373121,"twenty":1.763277,"median":4.142325,"eighty":23.555746,"marketCap":78720623},{"date":"2020-08-21","current":-0.356571,"twenty":1.753473,"median":4.14118,"eighty":23.545397,"marketCap":75228983},{"date":"2020-08-28","current":-0.353562,"twenty":1.748369,"median":4.135155,"eighty":23.541135,"marketCap":74594139},{"date":"2020-09-04","current":-0.330994,"twenty":1.739311,"median":4.12913,"eighty":23.540628,"marketCap":69832811},{"date":"2020-09-11","current":-0.321967,"twenty":1.735731,"median":4.11708,"eighty":23.528183,"marketCap":67928280},{"date":"2020-09-18","current":-0.315949,"twenty":1.729507,"median":4.088963,"eighty":23.515678,"marketCap":66658592},{"date":"2020-09-25","current":-0.303913,"twenty":1.724061,"median":4.08093,"eighty":23.512872,"marketCap":64119217},{"date":"2020-10-02","current":-0.335508,"twenty":1.721155,"median":4.062855,"eighty":23.505565,"marketCap":70785077},{"date":"2020-10-09","current":-0.349048,"twenty":1.709118,"median":4.024697,"eighty":23.499765,"marketCap":73641873},{"date":"2020-10-16","current":-0.314444,"twenty":1.6899,"median":3.49084,"eighty":23.48763,"marketCap":66341170},{"date":"2020-10-23","current":-0.303913,"twenty":1.680487,"median":2.92946,"eighty":23.479024,"marketCap":64119217},{"date":"2020-10-30","current":-0.28285,"twenty":1.671636,"median":2.901471,"eighty":23.474204,"marketCap":59675311},{"date":"2020-11-06","current":-0.317044,"twenty":1.669001,"median":2.893012,"eighty":23.46316,"marketCap":68283910},{"date":"2020-11-13","current":-0.410817,"twenty":1.660341,"median":2.891803,"eighty":23.457665,"marketCap":88480560},{"date":"2020-11-20","current":-0.482264,"twenty":1.638881,"median":2.890595,"eighty":23.453467,"marketCap":103868483},{"date":"2020-11-27","current":-0.55371,"twenty":1.628025,"median":2.888178,"eighty":23.445171,"marketCap":119256407},{"date":"2020-12-04","current":-0.614737,"twenty":1.126039,"median":2.87972,"eighty":23.434129,"marketCap":132400258},{"date":"2020-12-11","current":-0.584968,"twenty":-0.285558,"median":2.864009,"eighty":23.429934,"marketCap":125988623},{"date":"2020-12-18","current":-0.580502,"twenty":-0.300302,"median":2.849508,"eighty":23.424434,"marketCap":125026878},{"date":"2020-12-24","current":-0.601341,"twenty":-0.300904,"median":2.831381,"eighty":23.416184,"marketCap":129515022},{"date":"2020-12-31","current":-0.593899,"twenty":-0.303913,"median":2.820506,"eighty":23.416184,"marketCap":127912114},{"date":"2021-01-08","current":-0.640041,"twenty":-0.314444,"median":2.798754,"eighty":23.409199,"marketCap":137850148},{"date":"2021-01-15","current":-0.596876,"twenty":-0.317044,"median":2.779419,"eighty":23.409199,"marketCap":128553277},{"date":"2021-01-22","current":-0.626645,"twenty":-0.321601,"median":2.768543,"eighty":23.407301,"marketCap":134964912},{"date":"2021-01-29","current":-0.59241,"twenty":-0.325277,"median":2.721413,"eighty":23.39772,"marketCap":127591532},{"date":"2021-02-05","current":-0.59241,"twenty":-0.327985,"median":2.702078,"eighty":23.395443,"marketCap":127591532},{"date":"2021-02-12","current":-0.601341,"twenty":-0.329791,"median":2.692411,"eighty":23.395443,"marketCap":129515022},{"date":"2021-02-19","current":-0.538901,"twenty":-0.336712,"median":2.68516,"eighty":23.382999,"marketCap":116066912},{"date":"2021-02-26","current":-0.585684,"twenty":-0.343632,"median":2.668242,"eighty":23.374703,"marketCap":126142837},{"date":"2021-03-05","current":-0.656758,"twenty":-0.34965,"median":2.65374,"eighty":23.37052,"marketCap":141450494},{"date":"2021-03-12","current":-0.765058,"twenty":-0.355066,"median":2.642864,"eighty":23.367731,"marketCap":151261945},{"date":"2021-03-19","current":-0.773314,"twenty":-0.359667,"median":2.636822,"eighty":23.366463,"marketCap":152894262},{"date":"2021-03-26","current":-0.730698,"twenty":-0.372029,"median":2.628363,"eighty":23.358624,"marketCap":144468510},{"date":"2021-04-01","current":-0.728783,"twenty":-0.374023,"median":2.619904,"eighty":23.353962,"marketCap":144089825},{"date":"2021-04-09","current":-0.733571,"twenty":-0.377896,"median":2.605403,"eighty":23.351176,"marketCap":145036538},{"date":"2021-04-16","current":-0.733507,"twenty":-0.38625,"median":2.600569,"eighty":23.341486,"marketCap":145023804},{"date":"2021-04-23","current":-0.728759,"twenty":-0.394383,"median":2.571519,"eighty":23.333221,"marketCap":144085138},{"date":"2021-04-30","current":-0.716127,"twenty":-0.403156,"median":2.562972,"eighty":23.333221,"marketCap":141587548},{"date":"2021-05-07","current":12.280556,"twenty":-0.403908,"median":2.564193,"eighty":23.325539,"marketCap":145696522},{"date":"2021-05-14","current":11.159187,"twenty":-0.403156,"median":2.571519,"eighty":23.313402,"marketCap":132392591},{"date":"2021-05-21","current":12.000214,"twenty":-0.401278,"median":2.600569,"eighty":23.309699,"marketCap":142370539},{"date":"2021-05-28","current":12.008001,"twenty":-0.399569,"median":2.605403,"eighty":23.297233,"marketCap":142462928},{"date":"2021-06-04","current":12.880178,"twenty":-0.397861,"median":2.619904,"eighty":23.282034,"marketCap":152810430},{"date":"2021-06-11","current":13.61997,"twenty":-0.394449,"median":2.629572,"eighty":23.269611,"marketCap":161587329},{"date":"2021-06-18","current":13.253968,"twenty":-0.393243,"median":2.638031,"eighty":23.261298,"marketCap":157245073},{"date":"2021-06-25","current":13.191669,"twenty":-0.389358,"median":2.644073,"eighty":23.248872,"marketCap":156505966},{"date":"2021-07-02","current":12.545324,"twenty":-0.388504,"median":2.655244,"eighty":23.240563,"marketCap":148837728},{"date":"2021-07-09","current":12.958051,"twenty":-0.387002,"median":2.668242,"eighty":23.229518,"marketCap":153734314},{"date":"2021-07-16","current":12.630985,"twenty":-0.385121,"median":2.68516,"eighty":23.229518,"marketCap":149854001},{"date":"2021-07-23","current":12.919114,"twenty":-0.385121,"median":2.696036,"eighty":23.229518,"marketCap":153272372},{"date":"2021-07-30","current":13.627758,"twenty":-0.378951,"median":2.704495,"eighty":23.222589,"marketCap":161679717},{"date":"2021-08-06","current":2.692645,"twenty":-0.378071,"median":2.712954,"eighty":23.210305,"marketCap":158604894},{"date":"2021-08-13","current":2.590862,"twenty":-0.377634,"median":2.699661,"eighty":23.201855,"marketCap":152609520},{"date":"2021-08-20","current":2.612452,"twenty":-0.375728,"median":2.692528,"eighty":23.188037,"marketCap":153881266},{"date":"2021-08-27","current":2.524548,"twenty":-0.374625,"median":2.68516,"eighty":23.18112,"marketCap":148703443},{"date":"2021-09-03","current":2.529174,"twenty":-0.374625,"median":2.668242,"eighty":23.18112,"marketCap":148975960},{"date":"2021-09-10","current":2.444355,"twenty":-0.373422,"median":2.655244,"eighty":23.164533,"marketCap":143979815},{"date":"2021-09-17","current":2.424306,"twenty":-0.373121,"median":2.644073,"eighty":23.160386,"marketCap":142798908},{"date":"2021-09-24","current":2.478282,"twenty":-0.372318,"median":2.638031,"eighty":23.160386,"marketCap":145978273},{"date":"2021-10-01","current":2.530717,"twenty":-0.372,"median":2.630356,"eighty":23.160386,"marketCap":149066799},{"date":"2021-10-08","current":2.432017,"twenty":-0.36928,"median":2.624738,"eighty":23.127211,"marketCap":143253103},{"date":"2021-10-15","current":2.422764,"twenty":-0.367258,"median":2.617487,"eighty":23.118917,"marketCap":142708069},{"date":"2021-10-22","current":2.422764,"twenty":-0.362252,"median":2.608928,"eighty":23.109059,"marketCap":142708069},{"date":"2021-10-29","current":2.421222,"twenty":-0.359194,"median":2.602389,"eighty":23.099865,"marketCap":142617230},{"date":"2021-11-05","current":2.948349,"twenty":-0.357001,"median":2.601479,"eighty":23.065008,"marketCap":135081545},{"date":"2021-11-12","current":2.972158,"twenty":-0.356571,"median":2.605403,"eighty":23.045624,"marketCap":136172379},{"date":"2021-11-19","current":2.906683,"twenty":-0.355367,"median":2.614969,"eighty":23.037354,"marketCap":133172587},{"date":"2021-11-26","current":2.84716,"twenty":-0.355066,"median":2.621242,"eighty":23.035979,"marketCap":130445503},{"date":"2021-12-03","current":2.698354,"twenty":-0.354164,"median":2.629572,"eighty":23.023539,"marketCap":123627794},{"date":"2021-12-10","current":2.672561,"twenty":-0.353562,"median":2.636203,"eighty":23.015245,"marketCap":122446058},{"date":"2021-12-17","current":2.432487,"twenty":-0.351757,"median":2.629572,"eighty":23.015245,"marketCap":111446820},{"date":"2021-12-23","current":2.45828,"twenty":-0.349951,"median":2.622321,"eighty":23.001399,"marketCap":112628556},{"date":"2021-12-31","current":2.474153,"twenty":-0.348446,"median":2.614969,"eighty":22.97803,"marketCap":113355779},{"date":"2022-01-07","current":2.45828,"twenty":-0.34634,"median":2.605403,"eighty":22.973988,"marketCap":112628556},{"date":"2022-01-14","current":2.628911,"twenty":-0.344535,"median":2.605403,"eighty":22.973776,"marketCap":120446196},{"date":"2022-01-21","current":2.41463,"twenty":-0.344234,"median":2.601479,"eighty":22.969629,"marketCap":110628695},{"date":"2022-01-28","current":2.329315,"twenty":-0.342428,"median":2.593946,"eighty":22.948894,"marketCap":106719875},{"date":"2022-02-04","current":2.416614,"twenty":-0.33972,"median":2.588548,"eighty":22.928309,"marketCap":110719598},{"date":"2022-02-11","current":2.402726,"twenty":-0.338517,"median":2.584693,"eighty":22.90988,"marketCap":110083278},{"date":"2022-02-18","current":2.333283,"twenty":-0.337915,"median":2.570395,"eighty":22.898273,"marketCap":106901681},{"date":"2022-02-25","current":2.245983,"twenty":-0.335508,"median":2.564193,"eighty":22.890838,"marketCap":102901958},{"date":"2022-03-04","current":3.243244,"twenty":-0.330994,"median":2.564193,"eighty":22.871107,"marketCap":110020560},{"date":"2022-03-11","current":3.039484,"twenty":-0.330994,"median":2.570395,"eighty":22.849369,"marketCap":103108427},{"date":"2022-03-18","current":3.155514,"twenty":-0.32949,"median":2.584693,"eighty":22.828635,"marketCap":107044517},{"date":"2022-03-25","current":3.422888,"twenty":-0.32949,"median":2.588548,"eighty":22.828635,"marketCap":116114636},{"date":"2022-04-01","current":3.397664,"twenty":-0.328951,"median":2.593946,"eighty":22.827656,"marketCap":115258964},{"date":"2022-04-08","current":3.274067,"twenty":-0.327985,"median":2.601479,"eighty":22.8079,"marketCap":111066173},{"date":"2022-04-14","current":3.248843,"twenty":-0.327985,"median":2.605403,"eighty":22.791313,"marketCap":110210502},{"date":"2022-04-22","current":3.127915,"twenty":-0.327985,"median":2.612452,"eighty":22.72819,"marketCap":106108277},{"date":"2022-04-29","current":2.868089,"twenty":-0.326782,"median":2.621242,"eighty":22.688706,"marketCap":97294170},{"date":"2022-05-06","current":4.375842,"twenty":-0.326481,"median":2.628911,"eighty":22.657479,"marketCap":100429958},{"date":"2022-05-13","current":4.21343,"twenty":-0.325277,"median":2.630625,"eighty":22.634624,"marketCap":96702425},{"date":"2022-05-20","current":3.735933,"twenty":-0.322569,"median":2.636822,"eighty":22.60654,"marketCap":85743401},{"date":"2022-05-27","current":3.743573,"twenty":-0.321967,"median":2.642864,"eighty":22.591302,"marketCap":85918746},{"date":"2022-06-03","current":3.785593,"twenty":-0.321967,"median":2.651324,"eighty":22.545587,"marketCap":86883140},{"date":"2022-06-10","current":3.678634,"twenty":-0.321692,"median":2.668242,"eighty":22.48538,"marketCap":84428318},{"date":"2022-06-17","current":3.224057,"twenty":-0.320881,"median":2.67161,"eighty":22.421163,"marketCap":73995328},{"date":"2022-06-24","current":3.193497,"twenty":-0.319259,"median":2.686797,"eighty":22.367371,"marketCap":73293950},{"date":"2022-07-01","current":3.304276,"twenty":-0.317289,"median":2.691936,"eighty":22.325763,"marketCap":75836444},{"date":"2022-07-08","current":3.227877,"twenty":-0.316825,"median":2.692645,"eighty":22.317329,"marketCap":74083000},{"date":"2022-07-15","current":2.998678,"twenty":-0.315949,"median":2.699661,"eighty":22.30517,"marketCap":68822669},{"date":"2022-07-22","current":3.055978,"twenty":-0.315949,"median":2.704495,"eighty":22.284437,"marketCap":70137752},{"date":"2022-07-29","current":3.174397,"twenty":-0.315648,"median":2.716828,"eighty":22.263703,"marketCap":72855589},{"date":"2022-08-05","current":5.232925,"twenty":-0.314444,"median":2.726247,"eighty":22.238823,"marketCap":77625212},{"date":"2022-08-12","current":5.466621,"twenty":-0.314444,"median":2.760853,"eighty":22.205649,"marketCap":81091851},{"date":"2022-08-19","current":5.438471,"twenty":-0.312338,"median":2.772168,"eighty":22.201502,"marketCap":80674282},{"date":"2022-08-26","current":5.815674,"twenty":-0.303913,"median":2.785945,"eighty":22.182759,"marketCap":86269703},{"date":"2022-09-02","current":5.460991,"twenty":-0.303612,"median":2.798754,"eighty":22.174132,"marketCap":81008337},{"date":"2022-09-09","current":5.427211,"twenty":-0.302408,"median":2.815672,"eighty":22.174132,"marketCap":80507255},{"date":"2022-09-16","current":5.179496,"twenty":-0.300904,"median":2.822922,"eighty":22.164182,"marketCap":76832650},{"date":"2022-09-23","current":4.898002,"twenty":-0.300904,"median":2.831036,"eighty":22.164182,"marketCap":72656962},{"date":"2022-09-30","current":4.588358,"twenty":-0.300904,"median":2.842292,"eighty":22.164182,"marketCap":68063706},{"date":"2022-10-07","current":4.802294,"twenty":-0.300904,"median":2.861593,"eighty":22.122715,"marketCap":71237228},{"date":"2022-10-14","current":4.644657,"twenty":-0.300904,"median":2.866049,"eighty":22.122715,"marketCap":68898843},{"date":"2022-10-21","current":4.802294,"twenty":-0.299399,"median":2.878511,"eighty":22.101982,"marketCap":71237228},{"date":"2022-10-28","current":5.731225,"twenty":-0.297895,"median":2.885762,"eighty":22.101982,"marketCap":85016997},{"date":"2022-11-04","current":5.658037,"twenty":-0.294886,"median":2.890595,"eighty":22.081248,"marketCap":83931318},{"date":"2022-11-11","current":3.269547,"twenty":-0.287363,"median":2.891803,"eighty":22.060514,"marketCap":82896095},{"date":"2022-11-18","current":3.224437,"twenty":-0.28285,"median":2.893012,"eighty":22.039781,"marketCap":81752380},{"date":"2022-11-25","current":3.264743,"twenty":-0.281646,"median":2.900263,"eighty":22.039781,"marketCap":82774284},{"date":"2022-12-02","current":3.208315,"twenty":-0.278938,"median":2.909515,"eighty":22.039781,"marketCap":81343618},{"date":"2022-12-09","current":3.027746,"twenty":0.690334,"median":2.920572,"eighty":22.023194,"marketCap":76765484},{"date":"2022-12-16","current":2.937462,"twenty":1.319576,"median":2.928984,"eighty":21.985873,"marketCap":74476418},{"date":"2022-12-23","current":2.498939,"twenty":1.458571,"median":2.923052,"eighty":21.878059,"marketCap":63358094},{"date":"2022-12-30","current":2.663385,"twenty":1.56152,"median":2.918116,"eighty":21.803418,"marketCap":67527465},{"date":"2023-01-06","current":2.889096,"twenty":1.56152,"median":2.920572,"eighty":21.803418,"marketCap":73250132},{"date":"2023-01-13","current":3.121255,"twenty":1.56152,"median":2.934238,"eighty":21.803418,"marketCap":79136303},{"date":"2023-01-20","current":3.163173,"twenty":1.56152,"median":2.940687,"eighty":21.803418,"marketCap":80199084},{"date":"2023-01-27","current":3.03742,"twenty":1.56152,"median":2.963813,"eighty":21.803418,"marketCap":77010741},{"date":"2023-02-03","current":3.089011,"twenty":1.56152,"median":2.97938,"eighty":21.803418,"marketCap":78318780},{"date":"2023-02-10","current":2.995502,"twenty":1.56152,"median":2.986046,"eighty":21.803418,"marketCap":75947961},{"date":"2023-02-17","current":3.069664,"twenty":1.56152,"median":2.995967,"eighty":21.803418,"marketCap":77828265},{"date":"2023-02-24","current":3.101909,"twenty":1.56152,"median":3.006318,"eighty":21.803418,"marketCap":78645789},{"date":"2023-03-03","current":7.166438,"twenty":1.56152,"median":3.021298,"eighty":21.803418,"marketCap":76129066},{"date":"2023-03-10","current":6.673589,"twenty":1.565877,"median":3.03742,"eighty":21.803418,"marketCap":70893541},{"date":"2023-03-17","current":6.627828,"twenty":1.596379,"median":3.047969,"eighty":21.803418,"marketCap":70407414},{"date":"2023-03-24","current":7.581198,"twenty":1.601086,"median":3.061417,"eighty":21.803418,"marketCap":80535062},{"date":"2023-03-31","current":7.413404,"twenty":1.645072,"median":3.077506,"eighty":21.786831,"marketCap":78752596},{"date":"2023-04-06","current":7.192223,"twenty":1.601086,"median":3.08741,"eighty":21.803418,"marketCap":76402982},{"date":"2023-04-14","current":7.390524,"twenty":1.5571,"median":3.105133,"eighty":21.820005,"marketCap":78509533},{"date":"2023-04-21","current":7.375972,"twenty":1.513114,"median":3.121255,"eighty":21.836592,"marketCap":78354950},{"date":"2023-04-28","current":6.610326,"twenty":1.469128,"median":3.128557,"eighty":21.853179,"marketCap":70221497},{"date":"2023-05-05","current":6.094842,"twenty":1.469128,"median":3.146532,"eighty":21.853179,"marketCap":64745508},{"date":"2023-05-12","current":6.315875,"twenty":1.469128,"median":3.161027,"eighty":21.853179,"marketCap":69335675},{"date":"2023-05-19","current":6.24252,"twenty":1.469128,"median":3.171711,"eighty":21.853179,"marketCap":68530383},{"date":"2023-05-26","current":5.892774,"twenty":1.469128,"median":3.174891,"eighty":21.853179,"marketCap":64690871},{"date":"2023-06-02","current":6.111565,"twenty":1.469128,"median":3.178756,"eighty":21.853179,"marketCap":67092760},{"date":"2023-06-09","current":6.149999,"twenty":1.469128,"median":3.189323,"eighty":21.853179,"marketCap":67514692},{"date":"2023-06-16","current":6.082393,"twenty":1.469128,"median":3.199227,"eighty":21.853179,"marketCap":66772508},{"date":"2023-06-23","current":6.049574,"twenty":1.458571,"median":3.208315,"eighty":21.878059,"marketCap":66412225},{"date":"2023-06-30","current":6.257426,"twenty":1.448015,"median":3.216397,"eighty":21.902939,"marketCap":68694019},{"date":"2023-07-07","current":6.250133,"twenty":1.448015,"median":3.224292,"eighty":21.902939,"marketCap":68613956},{"date":"2023-07-14","current":6.578319,"twenty":1.448015,"median":3.243521,"eighty":21.902939,"marketCap":72216789},{"date":"2023-07-21","current":6.702301,"twenty":1.448015,"median":3.24834,"eighty":21.902939,"marketCap":73577860},{"date":"2023-07-28","current":6.578319,"twenty":1.448015,"median":3.264991,"eighty":21.902939,"marketCap":72216789},{"date":"2023-08-04","current":6.184495,"twenty":1.448015,"median":3.286333,"eighty":21.902939,"marketCap":67893390},{"date":"2023-08-11","current":6.351685,"twenty":1.448015,"median":3.322273,"eighty":21.902939,"marketCap":70535467},{"date":"2023-08-18","current":6.122833,"twenty":1.448015,"median":3.390097,"eighty":21.902939,"marketCap":67994059},{"date":"2023-08-25","current":6.050115,"twenty":1.448015,"median":3.429194,"eighty":21.902939,"marketCap":67186529},{"date":"2023-09-01","current":6.166463,"twenty":1.448015,"median":3.730203,"eighty":21.902939,"marketCap":68478577},{"date":"2023-09-08","current":5.810147,"twenty":1.448015,"median":3.743573,"eighty":21.902939,"marketCap":64521678},{"date":"2023-09-15","current":6.006485,"twenty":1.448015,"median":3.764583,"eighty":21.902939,"marketCap":66702011},{"date":"2023-09-22","current":5.868321,"twenty":1.448015,"median":4.024697,"eighty":21.902939,"marketCap":65167703},{"date":"2023-09-29","current":5.991941,"twenty":1.448015,"median":4.078921,"eighty":21.902939,"marketCap":66540504},{"date":"2023-10-06","current":5.970126,"twenty":1.448015,"median":4.113063,"eighty":21.902939,"marketCap":66298245},{"date":"2023-10-13","current":5.82469,"twenty":1.448015,"median":4.135155,"eighty":21.902939,"marketCap":64683185},{"date":"2023-10-20","current":5.263018,"twenty":1.448015,"median":4.142325,"eighty":21.902939,"marketCap":58445820},{"date":"2023-10-27","current":5.453103,"twenty":1.416345,"median":4.14118,"eighty":21.97758,"marketCap":60556704},{"date":"2023-11-03","current":5.639187,"twenty":1.416345,"median":4.14118,"eighty":14.071633,"marketCap":62623174},{"date":"2023-11-10","current":4.597236,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60968545},{"date":"2023-11-17","current":4.691483,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":62218453},{"date":"2023-11-24","current":4.594442,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60931496},{"date":"2023-12-01","current":4.552014,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60368804},{"date":"2023-12-08","current":5.091467,"twenty":1.426902,"median":4.14118,"eighty":13.959496,"marketCap":67523030},{"date":"2023-12-15","current":5.430898,"twenty":1.426902,"median":4.14118,"eighty":13.959496,"marketCap":72024565},{"date":"2023-12-22","current":6.121882,"twenty":1.426902,"median":4.144334,"eighty":13.959496,"marketCap":81188405},{"date":"2023-12-29","current":5.921861,"twenty":1.416345,"median":4.173313,"eighty":13.99376,"marketCap":78535715},{"date":"2024-01-05","current":5.994596,"twenty":1.319576,"median":4.201799,"eighty":14.009335,"marketCap":79500329},{"date":"2024-01-12","current":6.030963,"twenty":1.319576,"median":4.247621,"eighty":14.009335,"marketCap":79982637},{"date":"2024-01-19","current":5.897615,"twenty":1.222807,"median":4.282189,"eighty":14.024909,"marketCap":78214176},{"date":"2024-01-26","current":5.909738,"twenty":1.319576,"median":4.311888,"eighty":14.009335,"marketCap":78374946},{"date":"2024-02-02","current":6.079454,"twenty":1.319576,"median":4.327955,"eighty":14.009335,"marketCap":80625713},{"date":"2024-02-09","current":5.976412,"twenty":1.319576,"median":4.350046,"eighty":14.009335,"marketCap":79259176},{"date":"2024-02-16","current":6.085515,"twenty":1.319576,"median":4.362096,"eighty":14.009335,"marketCap":80706098},{"date":"2024-02-23","current":6.321904,"twenty":1.319576,"median":4.386196,"eighty":14.009335,"marketCap":83841096},{"date":"2024-03-01","current":6.697703,"twenty":1.416345,"median":4.576259,"eighty":13.99376,"marketCap":88824938},{"date":"2024-03-08","current":3.802021,"twenty":1.416345,"median":4.594442,"eighty":13.99376,"marketCap":85127249},{"date":"2024-03-15","current":3.670771,"twenty":1.416345,"median":4.552014,"eighty":13.627758,"marketCap":82188558},{"date":"2024-03-22","current":4.518879,"twenty":1.416345,"median":4.374799,"eighty":13.542097,"marketCap":101177708},{"date":"2024-03-28","current":4.473036,"twenty":1.416345,"median":4.324209,"eighty":13.253968,"marketCap":100151267},{"date":"2024-04-05","current":4.548166,"twenty":1.319576,"median":4.316791,"eighty":13.048383,"marketCap":101833436},{"date":"2024-04-12","current":4.421557,"twenty":1.319576,"median":4.316791,"eighty":12.951821,"marketCap":98998672},{"date":"2024-04-19","current":4.434543,"twenty":1.319576,"median":4.316791,"eighty":12.824109,"marketCap":99289417},{"date":"2024-04-26","current":4.434543,"twenty":1.416345,"median":4.324209,"eighty":12.732219,"marketCap":99289417},{"date":"2024-05-03","current":4.212125,"twenty":1.416345,"median":4.309328,"eighty":12.514175,"marketCap":94309475},{"date":"2024-05-10","current":3.932803,"twenty":1.416345,"median":4.212125,"eighty":12.280556,"marketCap":98662220},{"date":"2024-05-17","current":3.918344,"twenty":1.416345,"median":4.14347,"eighty":12.078087,"marketCap":98299491},{"date":"2024-05-24","current":3.756405,"twenty":1.416345,"median":3.988402,"eighty":12.000214,"marketCap":94236929},{"date":"2024-05-31","current":3.606033,"twenty":1.416345,"median":3.918344,"eighty":11.314932,"marketCap":90464550},{"date":"2024-06-07","current":3.788005,"twenty":1.416345,"median":3.860508,"eighty":9.717873,"marketCap":95029691},{"date":"2024-06-14","current":3.851139,"twenty":1.319576,"median":3.804358,"eighty":7.887548,"marketCap":96613519},{"date":"2024-06-21","current":3.893228,"twenty":1.222807,"median":3.802673,"eighty":7.521707,"marketCap":97669405},{"date":"2024-06-28","current":3.839113,"twenty":0.932501,"median":3.800901,"eighty":7.413404,"marketCap":96311838},{"date":"2024-07-05","current":3.953355,"twenty":0.932501,"median":3.800901,"eighty":7.375972,"marketCap":99177812},{"date":"2024-07-12","current":4.109685,"twenty":0.932501,"median":3.800901,"eighty":7.207477,"marketCap":103099673},{"date":"2024-07-15","current":4.193863,"twenty":0.932501,"median":3.800901,"eighty":7.194036,"marketCap":105211444},{"date":"2024-08-02","current":4.458422,"twenty":-0.282248,"median":3.785593,"eighty":6.893892,"marketCap":111848438},{"date":"2024-08-09","current":4.330188,"twenty":-0.282248,"median":3.785593,"eighty":6.71397,"marketCap":112034952},{"date":"2024-08-16","current":4.293515,"twenty":-0.282248,"median":3.785593,"eighty":6.684421,"marketCap":111086122},{"date":"2024-08-23","current":4.437385,"twenty":-0.282248,"median":3.785593,"eighty":6.626684,"marketCap":114808456},{"date":"2024-08-30","current":4.443027,"twenty":-0.282248,"median":3.785593,"eighty":6.593741,"marketCap":114954430},{"date":"2024-09-06","current":4.420459,"twenty":-0.282248,"median":3.785593,"eighty":6.572485,"marketCap":114370534},{"date":"2024-09-13","current":4.358398,"twenty":-0.282248,"median":3.785593,"eighty":6.489344,"marketCap":112764822},{"date":"2024-09-20","current":4.358398,"twenty":-0.282248,"median":3.785593,"eighty":6.439122,"marketCap":112764822},{"date":"2024-09-27","current":4.403533,"twenty":-0.282248,"median":3.785593,"eighty":6.403286,"marketCap":113932613},{"date":"2024-10-04","current":4.45149,"twenty":-0.282248,"median":3.785593,"eighty":6.389947,"marketCap":115173391},{"date":"2024-10-11","current":4.474057,"twenty":-0.282248,"median":3.785593,"eighty":6.366105,"marketCap":115757286},{"date":"2024-10-18","current":4.327367,"twenty":-0.282248,"median":3.785593,"eighty":6.321904,"marketCap":111961965},{"date":"2024-10-25","current":4.321725,"twenty":-0.282248,"median":3.785593,"eighty":6.261802,"marketCap":111815992},{"date":"2024-10-31","current":4.27941,"twenty":-0.282248,"median":3.785593,"eighty":6.240491,"marketCap":110721187},{"date":"2024-11-08","current":4.441959,"twenty":-0.282549,"median":3.784012,"eighty":6.202291,"marketCap":116779104},{"date":"2024-11-15","current":4.397133,"twenty":-0.282549,"median":3.784012,"eighty":6.149605,"marketCap":115600635},{"date":"2024-11-22","current":4.560596,"twenty":-0.282549,"median":3.784012,"eighty":6.139391,"marketCap":119898057},{"date":"2024-11-29","current":4.732231,"twenty":-0.282549,"median":3.784012,"eighty":6.120618,"marketCap":124410349},{"date":"2024-12-06","current":4.80034,"twenty":-0.282549,"median":3.784012,"eighty":6.102487,"marketCap":126200941},{"date":"2024-12-13","current":4.66957,"twenty":-0.282549,"median":3.784012,"eighty":6.088852,"marketCap":122763004},{"date":"2024-12-20","current":4.171011,"twenty":-0.282549,"median":3.784012,"eighty":6.078382,"marketCap":109655869},{"date":"2024-12-27","current":4.405306,"twenty":-0.282549,"median":3.784012,"eighty":6.067331,"marketCap":115815506},{"date":"2025-01-03","current":4.489762,"twenty":-0.282549,"median":3.784012,"eighty":6.059453,"marketCap":118035841},{"date":"2025-01-10","current":4.745853,"twenty":-0.28285,"median":3.782431,"eighty":6.049147,"marketCap":124768467},{"date":"2025-01-17","current":4.822135,"twenty":-0.28285,"median":3.782431,"eighty":6.037025,"marketCap":126773931},{"date":"2025-01-24","current":4.890244,"twenty":-0.28285,"median":3.782431,"eighty":6.035572,"marketCap":128564523},{"date":"2025-01-31","current":4.794891,"twenty":-0.28285,"median":3.782431,"eighty":6.016756,"marketCap":126057694},{"date":"2025-02-07","current":5.012841,"twenty":-0.28285,"median":3.782431,"eighty":6.002169,"marketCap":131787589},{"date":"2025-02-14","current":5.165406,"twenty":-0.28285,"median":3.782431,"eighty":5.999213,"marketCap":135798516},{"date":"2025-02-21","current":5.375182,"twenty":-0.28285,"median":3.782431,"eighty":5.991941,"marketCap":141313540},{"date":"2025-02-28","current":5.6231,"twenty":-0.28285,"median":3.782431,"eighty":5.970126,"marketCap":147831296},{"date":"2025-03-07","current":5.080493,"twenty":-0.283753,"median":3.782268,"eighty":5.951081,"marketCap":148690780},{"date":"2025-03-14","current":5.481842,"twenty":-0.283753,"median":3.782268,"eighty":5.922788,"marketCap":160437065},{"date":"2025-03-21","current":11.366901,"twenty":-0.283753,"median":3.788005,"eighty":5.926495,"marketCap":332675095},{"date":"2025-03-28","current":5.041233,"twenty":-0.283753,"median":3.800901,"eighty":5.92678,"marketCap":147541761},{"date":"2025-04-04","current":4.869586,"twenty":-0.283753,"median":3.829511,"eighty":5.92678,"marketCap":142518184},{"date":"2025-04-11","current":4.150082,"twenty":-0.28285,"median":3.860508,"eighty":5.926495,"marketCap":121460451},{"date":"2025-04-17","current":4.12892,"twenty":-0.28285,"median":3.878196,"eighty":5.926495,"marketCap":120841106},{"date":"2025-04-25","current":4.180649,"twenty":-0.283753,"median":3.918344,"eighty":5.92678,"marketCap":122355061},{"date":"2025-04-29","current":4.352296,"twenty":-0.283753,"median":3.931357,"eighty":5.92678,"marketCap":127378638}],"updateTime":1746014331886}}}